| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CUEDC2 |
| Uniprot No | Q9H467 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-287aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSMELERIV SAALLAFVQT HLPEADLSGL DEVIFSYVLG VLEDLGPSGP SEENFDMEAF TEMMEAYVPG FAHIPRGTIG DMMQKLSGQL SDARNKENLQ PQSSGVQGQV PISPEPLQRP EMLKEETRSS AAAAADTQDE ATGAEEELLP GVDVLLEVFP TCSVEQAQWV LAKARGDLEE AVQMLVEGKE EGPAAWEGPN QDLPRRLRGP QKDELKSFIL QKYMMVDSAE DQKIHRPMAP KEAPKKLIRY IDNQVVSTKG ERFKDVRNPE AEEMKATYIN LKPARKYRFH |
| 预测分子量 | 34 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于 **CUEDC2重组蛋白** 的3篇示例参考文献(注：文献为示例，具体内容需根据实际检索调整)：
---
1. **文献名称**: *"CUEDC2 promotes tumor progression by enhancing EGFR signaling and induces epithelial-mesenchymal transition in head and neck squamous cell carcinoma"*
**作者**: Li Y, et al.
**摘要**: 研究报道CUEDC2重组蛋白通过增强EGFR信号通路促进头颈鳞癌的肿瘤进展，并诱导上皮间质转化(EMT)，提示其在癌症转移中的潜在作用。
2. **文献名称**: *"CUEDC2 regulates the inflammatory response by modulating NF-κB nuclear translocation in macrophages"*
**作者**: Wang X, et al.
**摘要**: 该研究利用重组CUEDC2蛋白，发现其通过抑制NF-κB的核转位减少巨噬细胞中促炎细胞因子(如TNF-α、IL-6)的释放，为炎症性疾病治疗提供新靶点。
3. **文献名称**: *"CUEDC2 interacts with BRCA1 and regulates its stability in DNA damage repair"*
**作者**: Zhang H, et al.
**摘要**: 研究揭示CUEDC2重组蛋白与BRCA1相互作用，通过泛素-蛋白酶体通路调控BRCA1稳定性，影响DNA损伤修复功能，可能参与肿瘤基因组不稳定性机制。
---
**建议**：可通过 **PubMed/Google Scholar** 检索关键词“CUEDC2 recombinant protein”或“CUEDC2 overexpression”获取最新文献，重点关注其在癌症、炎症或信号通路中的功能研究。
CUEDC2 (CUE domain-containing protein 2) is a ubiquitin-binding protein implicated in regulating critical cellular processes, including cell cycle progression, inflammatory responses, and cancer development. The protein contains a conserved CUE domain, a ubiquitin-binding motif that facilitates interactions with ubiquitinated substrates, positioning it as a modulator of ubiquitin-dependent signaling pathways. CUEDC2 is known to interact with key regulators such as the anaphase-promoting complex/cyclosome (APC/C), where it promotes the degradation of specific cell cycle proteins, and the estrogen receptor-α (ERα), influencing hormone-responsive pathways.
Research highlights its dual role in cancer biology. In ovarian and breast cancers, CUEDC2 overexpression correlates with poor prognosis by enhancing ERα degradation, leading to hormone resistance, or by stabilizing oncoproteins through deubiquitination. Conversely, in hepatocellular carcinoma, CUEDC2 may act as a tumor suppressor by promoting apoptosis. Beyond oncology, CUEDC2 regulates macrophage polarization and NF-κB signaling, linking it to inflammatory diseases like atherosclerosis.
Recombinant CUEDC2 protein, produced via bacterial or mammalian expression systems, is essential for in vitro studies to dissect its molecular interactions, enzymatic activity, and structural features. This tool enables researchers to explore its binding partners, ubiquitination dynamics, and therapeutic potential. Its role in modulating drug resistance and immune responses further underscores its relevance in developing targeted therapies. Despite progress, the context-dependent mechanisms of CUEDC2 in different tissues and diseases remain an active area of investigation, emphasizing the need for further functional and translational studies.
×
